139 related articles for article (PubMed ID: 27758717)
1. Pharmacological Activation of Protein Phosphatase 2 A (PP2A): A Novel Strategy to Fight Against Human Malignancies?
Carratù MR; Signorile A; De Rasmo D; Reale A; Vacca A
Curr Med Chem; 2016; 23(38):4286-4296. PubMed ID: 27758717
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic targeting of PP2A.
O'Connor CM; Perl A; Leonard D; Sangodkar J; Narla G
Int J Biochem Cell Biol; 2018 Mar; 96():182-193. PubMed ID: 29107183
[TBL] [Abstract][Full Text] [Related]
3. Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation.
Chen KF; Yu HC; Liu TH; Lee SS; Chen PJ; Cheng AL
J Hepatol; 2010 Jan; 52(1):88-95. PubMed ID: 19913321
[TBL] [Abstract][Full Text] [Related]
4. Multiple pathways regulated by the tumor suppressor PP2A in transformation.
Westermarck J; Hahn WC
Trends Mol Med; 2008 Apr; 14(4):152-60. PubMed ID: 18329957
[TBL] [Abstract][Full Text] [Related]
5. Development of novel PP2A activators for use in the treatment of acute myeloid leukaemia.
Toop HD; Dun MD; Ross BK; Flanagan HM; Verrills NM; Morris JC
Org Biomol Chem; 2016 May; 14(20):4605-16. PubMed ID: 27102578
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic relevance of the protein phosphatase 2A in cancer.
Cunningham CE; Li S; Vizeacoumar FS; Bhanumathy KK; Lee JS; Parameswaran S; Furber L; Abuhussein O; Paul JM; McDonald M; Templeton SD; Shukla H; El Zawily AM; Boyd F; Alli N; Mousseau DD; Geyer R; Bonham K; Anderson DH; Yan J; Yu-Lee LY; Weaver BA; Uppalapati M; Ruppin E; Sablina A; Freywald A; Vizeacoumar FJ
Oncotarget; 2016 Sep; 7(38):61544-61561. PubMed ID: 27557495
[TBL] [Abstract][Full Text] [Related]
7. Covalent Ligand Discovery against Druggable Hotspots Targeted by Anti-cancer Natural Products.
Grossman EA; Ward CC; Spradlin JN; Bateman LA; Huffman TR; Miyamoto DK; Kleinman JI; Nomura DK
Cell Chem Biol; 2017 Nov; 24(11):1368-1376.e4. PubMed ID: 28919038
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of Novel FTY720 Analogs with Anticancer Activity through PP2A Activation.
Shrestha J; Ki SH; Shin SM; Kim SW; Lee JY; Jun HS; Lee T; Kim S; Baek DJ; Park EY
Molecules; 2018 Oct; 23(11):. PubMed ID: 30355990
[TBL] [Abstract][Full Text] [Related]
9. Functional importance of PP2A regulatory subunit loss in breast cancer.
Watt LF; Panicker N; Mannan A; Copeland B; Kahl RGS; Dun MD; Young B; Roselli S; Verrills NM
Breast Cancer Res Treat; 2017 Nov; 166(1):117-131. PubMed ID: 28744751
[TBL] [Abstract][Full Text] [Related]
10. Mouse model for probing tumor suppressor activity of protein phosphatase 2A in diverse signaling pathways.
Walter G; Ruediger R
Cell Cycle; 2012 Feb; 11(3):451-9. PubMed ID: 22262169
[TBL] [Abstract][Full Text] [Related]
11. Structure, regulation, and pharmacological modulation of PP2A phosphatases.
Lambrecht C; Haesen D; Sents W; Ivanova E; Janssens V
Methods Mol Biol; 2013; 1053():283-305. PubMed ID: 23860660
[TBL] [Abstract][Full Text] [Related]
12. Disruption and inactivation of the PP2A complex promotes the proliferation and angiogenesis of hemangioma endothelial cells through activating AKT and ERK.
Xie F; Bao X; Yu J; Chen W; Wang L; Zhang Z; Xu Q
Oncotarget; 2015 Sep; 6(28):25660-76. PubMed ID: 26308070
[TBL] [Abstract][Full Text] [Related]
13. Phosphorylation of protein phosphatase 2A facilitated an early stage of chemical carcinogenesis.
Ishii Y; Kuroda K; Matsushita K; Yokoo Y; Takasu S; Kijima A; Nohmi T; Ogawa K; Umemura T
Toxicol Appl Pharmacol; 2017 Dec; 336():75-83. PubMed ID: 29054680
[TBL] [Abstract][Full Text] [Related]
14. Deregulation of the protein phosphatase 2A, PP2A in cancer: complexity and therapeutic options.
Grech G; Baldacchino S; Saliba C; Grixti MP; Gauci R; Petroni V; Fenech AG; Scerri C
Tumour Biol; 2016 Sep; 37(9):11691-11700. PubMed ID: 27444275
[TBL] [Abstract][Full Text] [Related]
15. The effect of a PP2A inhibitor on the nuclear receptor corepressor pathway in glioma.
Lu J; Zhuang Z; Song DK; Mehta GU; Ikejiri B; Mushlin H; Park DM; Lonser RR
J Neurosurg; 2010 Aug; 113(2):225-33. PubMed ID: 20001590
[TBL] [Abstract][Full Text] [Related]
16. Growth of the pancreatic cancer cell line PANC-1 is inhibited by protein phosphatase 2A inhibitors through overactivation of the c-Jun N-terminal kinase pathway.
Li W; Chen Z; Gong FR; Zong Y; Chen K; Li DM; Yin H; Duan WM; Miao Y; Tao M; Han X; Xu ZK
Eur J Cancer; 2011 Nov; 47(17):2654-64. PubMed ID: 21958460
[TBL] [Abstract][Full Text] [Related]
17. Potential anti-tumor effects of FTY720 associated with PP2A activation: a brief review.
Cristóbal I; Madoz-Gúrpide J; Manso R; González-Alonso P; Rojo F; García-Foncillas J
Curr Med Res Opin; 2016 Jun; 32(6):1137-41. PubMed ID: 26950691
[TBL] [Abstract][Full Text] [Related]
18. Activation of the Tumor Suppressor PP2A Emerges as a Potential Therapeutic Strategy for Treating Prostate Cancer.
Cristóbal I; González-Alonso P; Daoud L; Solano E; Torrejón B; Manso R; Madoz-Gúrpide J; Rojo F; García-Foncillas J
Mar Drugs; 2015 May; 13(6):3276-86. PubMed ID: 26023836
[TBL] [Abstract][Full Text] [Related]
19. Protein phosphatase 2A as a potential target for anticancer therapy.
Kalev P; Sablina AA
Anticancer Agents Med Chem; 2011 Jan; 11(1):38-46. PubMed ID: 21288198
[TBL] [Abstract][Full Text] [Related]
20. Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth.
Sangodkar J; Perl A; Tohme R; Kiselar J; Kastrinsky DB; Zaware N; Izadmehr S; Mazhar S; Wiredja DD; O'Connor CM; Hoon D; Dhawan NS; Schlatzer D; Yao S; Leonard D; Borczuk AC; Gokulrangan G; Wang L; Svenson E; Farrington CC; Yuan E; Avelar RA; Stachnik A; Smith B; Gidwani V; Giannini HM; McQuaid D; McClinch K; Wang Z; Levine AC; Sears RC; Chen EY; Duan Q; Datt M; Haider S; Ma'ayan A; DiFeo A; Sharma N; Galsky MD; Brautigan DL; Ioannou YA; Xu W; Chance MR; Ohlmeyer M; Narla G
J Clin Invest; 2017 Jun; 127(6):2081-2090. PubMed ID: 28504649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
